Introduction {#sec1-1}
============

All-*trans*-retinoic acid given (ATRA) as induction or maintenance therapy results in improved disease-free survival and overall survival, as compared with chemotherapy alone, in patients with newly diagnosed acute promyelocytic leukemia ([@r1]).

In addition to this therapeutical effect, ATRA has been shown to affect cellular hemostatic properties. Several studies demonstrate that ATRA affects the hemostatic balance of the endothelium. Particularly, ATRA induces the expression of endothelial cell thrombomodulin, the membrane receptor that binds and inactivates thrombin. Intriguingly, thrombotic events have been reported in some series during ATRA therapy, including fatal myocardial infarction and cerebral thrombosis ([@r2]-[@r4]).

Here we present a rather uncommon side effect observed in a patient with acute promyelocytic leukemia during treatment with ATRA.

Case study {#sec1-2}
==========

A 20-year-old man, presented to the emergency department with easy fatigability, for almost one month, ecchymosis on the arms and legs, occasional epistaxis, and gum bleeding for the last 2 weeks.

On clinical examination he was found to have multiple bruises and ecchymosis on the upper and lower limbs, and on the abdomen. The other clinical parameters to the physical examination were unremarkable.

Initial lab. Tests showed white blood counts (WBC) of 5.6×10^9^/L (normal values: 4-10 ×10^9^), hemoglobin 12.4 gm/dl (normal values: 13.0-17.0), platelet counts 17×10^9^/L (normal values: 150-400×10^9^), prothrombin time (PT) 12.8 seconds (normal values: 9.4-12.5), activated partial thromboplastin time (aPTT) 24.3 seconds (normal values: 25.1-36.5), D-Dimer 3.6 mg/L (normal values: 0.0-0.49), fibrinogen 0.9 gm/l (normal values: 2.0-4.1 mg/L), and International Normalized Ration (INR) 1.1 (normal values: 0.8-1.2).

Peripheral smear showed a 20% of abnormal leukemic promyelocytes and 2% of circulating blasts, substantially the picture was suggestive of acute promyelocytic leukemia (APL) a subtype of acute myeloid leukemia (AML). Therefore, ATRA was started at a dose of 45 mg/m^2^ and PETHEMA protocol was started because of the confirmed diagnosis of APL intermediate risk, after bone marrow (BM) examination.

His admission in the hospital was uneventful, apart from headache. The curve of platelet counts from day 1 till day 46 of ATRA treatment is shown in [figure 1](#F1){ref-type="fig"}. During the treatment the patient developed a marked thrombocytosis, up to 1650×10^9^/L. The peripheral blood showed a moderate anemia, monocytosis, 1% of circulating blast and remarkable thrombocytosis.

![Platelet counts curve from day 1 till day 46 of ATRA treatment. Vertical line: platelet values are expressed in x 10^9^/L](ACTA-89-33-g001){#F1}

The BM aspirate, repeated on day 29, showed a trilineal hematopoiesis with 1% of blasts ([Figure 2](#F2){ref-type="fig"} A) and the BM biopsy section showed a mild hypercellularity for age (\~85%) with erythroid and megakaryocytic hyperplasia, and adequate granulopoiesis ([Figures 2 B and C](#F2){ref-type="fig"}).

![Peripheral blood smear showing marked thrombocytosis, 50x (A). Bone marrow biopsy (H&E) showing mild hypercellularity with megakaryocytic hyperplasia and prominent erythroid islands, 50x (B). Vwf immunostain highlighted megakaryocytic proliferation; scattered with no clusters and no significant atypia noted, 50x (C). CD34 immunostain highlighted mild increase in CD34 positivity with few adjacent cells, roughly estimated by \~4-5%, 50x (D)](ACTA-89-33-g002){#F2}

CD34 highlighted some scattered positivity with few adjacent cells, roughly estimated by \~4-5% ([Figure 2D](#F2){ref-type="fig"}). FISH analysis revealed abnormal hybridization signal pattern indicating *PML/RARA* rearrangement, t(15;17), in 2% of the cells analyzed indicating residual disease.

Because he was asymptomatic ATRA dosage was not modified. His platelet counts declined progressively (46^th^ day of hospitalisation) as shown in [figure 1](#F1){ref-type="fig"}.

Discussion {#sec1-3}
==========

The platelets production is regulated by thrombopoietin (TPO), a hormone usually produced by the liver and kidneys. Normal physiology of platelet production involves the clearance of TPO by high-affinity TPO receptors on platelets and formation of a steady TPO concentration, thereby providing a basal stimulation of bone marrow megakaryocytes and normal rate of platelet production. Old platelets are destroyed by phagocytosis in the spleen and by Kupffer cells in the liver ([@r5], [@r6]).

On a clinical level, thrombocytosis is classified "mild" at a platelet count between \>500×10^9^/L and \<700×10^9^/L; "moderate" at a platelet count between \>700×10^9^/L and \<900×10^9^/L; "severe" at a platelet count \>900×10^9^/L; and "extreme" at a platelet count \>1,000×10^9^/L ([@r7]). Thrombocytosis can be classified as primary or secondary. Primary thrombocytosis is divided into familial and essential. Generally, it is a reactive process caused by infection, chronic inflammation, iron deficiency, tissue damage, cancer, drugs and surgical or functional splenectomy.

Reactive or secondary thrombocytosis associated with malignancies has been established since the early 1870s, with an incidence of 10-57% ([@r8]). Possible mechanisms include an overproduction of cytokines/growth factors stimulating megakaryocytes and their precursors. However, in secondary thrombocytosis that can occur with malignancies, there can be upregulation of TPO production by the liver causing enhanced thrombopoiesis. Plasma TPO levels have also been shown to correlate with IL-6 ([@r9]).
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Essential thrombocytosis or thrombocythemia (ET) in adults is well known as a member of the family of myeloproliferative neoplasms (MPN), also including polycythemia vera (PV) and primary myelofibrosis (PMF). These disorders share several features, such as splenomegaly, growth factor independent hematopoiesis, and the potential to transform to acute myeloid leukemia (AML). Since identification of the *JAK2 V617F* mutation in 2005, and subsequently of mutations in relevant JAK-STAT pathway genes, these MPN are now relatively well-understood entities in adults ([@r10]).

Regardless of the cause of thrombocytosis, a high platelet count can be associated with vasomotor phenomena (headache, visual symptoms, nausea, chest pain, dysaesthesia, aphasia, dysarthria, vertigo, instability, shivering or erythromelalgia), thrombotic phenomena or haemorrhagic complications ([@r11]).

The occurrence of thrombosis during induction treatment with ATRA combined with aprotinin and chemotherapy was described in a young patient who was homozygous for factor VQ 506 mutation ([@r12]). Cases of acute renal failure, due to occlusion of renal vessels in a patient with APL treated with ATRA and tranexamic acid and with ATRA alone ([@r13]) have also been described. A patient with APL had fatal thromboembolism after receiving ATRA and tranexamic acid therapy ([@r14]).

In our patient thrombocytosis was probably caused by the excess production of cytokines mainly IL-6 induced by APL cells under the influence of ATRA.

Similar results were reported by Losada et al. ([@r15]) in two APL cases with platelet counts \>1000× 10^9^/L during ATRA therapy who were treated with recombinant interferon alpha. In both cases ATRA doses were not modified, no complications secondary to thrombocytosis were seen, and they subsequently achieved complete remission.

Escudier et al. ([@r16]) noted that thrombotic events were more common in patients suspected of having ATRA syndrome. ATRA syndrome is the most severe side effect occurring in about a quarter of patients, usually between the second day and the third week of treatment. It is a protean syndrome of fever, respiratory distress, pulmonary infiltrates, pleuropericardial effusions, and edema, more common among patients who present with a high white blood cell count or develop rapid leukocytosis. If not promptly recognized and treated, the ATRA syndrome can lead to death from progressive hypoxemia and multiorgan failure.

Our patient did not develop any thrombosis or bleeding complications, and his platelet counts started to recover on day 33 of ATRA treatment, indicating that in such type of thrombocytosis specific anti-platelet or cytoreduction therapy is not stricly required. Interestingly, the decrease in platelet counts seemed to be spontaneous rather than the effect of IFN-α which typically needs a median of 6 weeks to start its effect ([@r17]).

In summary, IL-6 seems to play an important role in the pathogenesis of the thrombocytosis induced by ATRA. However, it is unclear what are the precipitating factors for this rare phenomenon and whether it is caused by certain predisposing factors that might be related to patient's, disease pathogenesis or other unknown factors.
